Literature DB >> 23955332

Three-dimensional culture using human plasma-medium gel with fragmin/protamine microparticles for proliferation of various human cells.

Satoko Kishimoto1, Masayuki Ishihara, Makoto Takikawa, Megumi Takikawa, Yuki Sumi, Shingo Nakamura, Masanori Fujita, Toshinori Sato, Tomoharu Kiyosawa.   

Abstract

Fragmin/protamine microparticles (F/P MPs) have been used as carriers for the preservation and activation of cytokines in human plasma (HP)-Dulbecco's modified Eagle's medium (DMEM) gels. This study investigated a three-dimensional (3D) culture system using an HP-DMEM gel with 0.1 mg/mL F/P MPs and 5 ng/mL FGF-2 for the proliferation of human dermal fibroblast cells (DFCs), human microvascular endothelial cells (MVECs) and human coronary smooth muscle cells (SMCs), or 5 ng/mL interleukin (IL)-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) for a human hematopoietic cell line (TF-1 cells). DFCs, MVECs, SMCs and TF-1 cells grew rapidly under 3D culture conditions using a low-concentration HP (2 %)-DMEM gel with F/P MPs and FGF-2 (for DFCs, MVECs and SMCs) or IL-3/GM-CSF (for TF-1 cells) at doubling times of 22, 23, 25 and 18 h, respectively, without the use of animal serum, compared to under 2D culture conditions using low-concentration human serum (2 %)-DMEM with 5 ng/mL FGF-2 or IL-3/GM-CSF on F/P MP-coated plates at doubling times of approximately 26, 25, 40 and 20 h, respectively.

Entities:  

Year:  2013        PMID: 23955332      PMCID: PMC4158012          DOI: 10.1007/s10616-013-9628-5

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  16 in total

1.  Platelet-rich plasma (PRP): what is PRP and what is not PRP?

Authors:  R E Marx
Journal:  Implant Dent       Date:  2001       Impact factor: 2.454

2.  Fragmin/protamine microparticles as cell carriers to enhance viability of adipose-derived stromal cells and their subsequent effect on in vivo neovascularization.

Authors:  Shingo Nakamura; Satoko Kishimoto; Shin-ichiro Nakamura; Masaki Nambu; Masanori Fujita; Yoshihiro Tanaka; Yasutaka Mori; Masahiro Tagawa; Tadaaki Maehara; Masayuki Ishihara
Journal:  J Biomed Mater Res A       Date:  2010-03-15       Impact factor: 4.396

3.  Enhanced effect of platelet-rich plasma containing a new carrier on hair growth.

Authors:  Megumi Takikawa; Shinichiro Nakamura; Shingo Nakamura; Masayuki Ishirara; Satoko Kishimoto; Kaoru Sasaki; Satoshi Yanagibayashi; Ryuichi Azuma; Naoto Yamamoto; Tomoharu Kiyosawa
Journal:  Dermatol Surg       Date:  2011-08-24       Impact factor: 3.398

4.  In-laboratory removal of femoral sheath following protamine administration in patients having intracoronary stent implantation.

Authors:  M Pan; J Suárez de Lezo; A Medina; M Romero; E Hernández; J Segura; F Melian; F Wangüemert; M Landin; F Benítez; M Amat; F Velasco; A Torres
Journal:  Am J Cardiol       Date:  1997-11-15       Impact factor: 2.778

5.  PRP&F/P MPs improved survival of dorsal paired pedicle skin flaps in rats.

Authors:  Megumi Takikawa; Yuki Sumi; Masayuki Ishihara; Satoko Kishimoto; Shingo Nakamura; Satoshi Yanagibayashi; Hidemi Hattori; Ryuichi Azuma; Naoto Yamamoto; Tomoharu Kiyosawa
Journal:  J Surg Res       Date:  2011-06-23       Impact factor: 2.192

6.  Human embryonic stem cells express an immunogenic nonhuman sialic acid.

Authors:  Maria J Martin; Alysson Muotri; Fred Gage; Ajit Varki
Journal:  Nat Med       Date:  2005-01-30       Impact factor: 53.440

7.  Enhancement of vascularization and granulation tissue formation by growth factors in human platelet-rich plasma-containing fragmin/protamine microparticles.

Authors:  Megumi Takikawa; Shin-Ichiro Nakamura; Shingo Nakamura; Masaki Nambu; Masayuki Ishihara; Masanori Fujita; Satoko Kishimoto; Takashi Doumoto; Satoshi Yanagibayashi; Ryuichi Azuma; Naoto Yamamoto; Tomoharu Kiyosawa
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2011-03-22       Impact factor: 3.368

8.  Controlled release of FGF-2 using fragmin/protamine microparticles and effect on neovascularization.

Authors:  Shingo Nakamura; Yasuhiro Kanatani; Satoko Kishimoto; Shin-ichiro Nakamura; Chizuko Ohno; Takuya Horio; Fujita Masanori; Hidemi Hattori; Yoshihiro Tanaka; Tomoharu Kiyosawa; Tadaaki Maehara; Masayuki Ishihara
Journal:  J Biomed Mater Res A       Date:  2009-12       Impact factor: 4.396

9.  Preparation and characterization of low-molecular-weight heparin/protamine nanoparticles (LMW-H/P NPs) as FGF-2 carrier.

Authors:  Yasutaka Mori; Shingo Nakamura; Satoko Kishimoto; Mitsuyuki Kawakami; Satoshi Suzuki; Takemi Matsui; Masayuki Ishihara
Journal:  Int J Nanomedicine       Date:  2010-04-07

Review 10.  Heparan sulfate: a piece of information.

Authors:  M Salmivirta; K Lidholt; U Lindahl
Journal:  FASEB J       Date:  1996-09       Impact factor: 5.191

View more
  4 in total

1.  MiR-29b mimics promotes cell apoptosis of smooth muscle cells via targeting on MMP-2.

Authors:  Lingguang Shen; Yanhui Song; Yuqin Fu; Peipei Li
Journal:  Cytotechnology       Date:  2017-10-07       Impact factor: 2.058

Review 2.  Biomedical application of low molecular weight heparin/protamine nano/micro particles as cell- and growth factor-carriers and coating matrix.

Authors:  Masayuki Ishihara; Satoko Kishimoto; Makoto Takikawa; Hidemi Hattori; Shingo Nakamura; Masafumi Shimizu
Journal:  Int J Mol Sci       Date:  2015-05-22       Impact factor: 5.923

Review 3.  Recent Progress on Heparin-Protamine Particles for Biomedical Application.

Authors:  Yuuki Hata; Hiromi Miyazaki; Masayuki Ishihara; Shingo Nakamura
Journal:  Polymers (Basel)       Date:  2022-02-25       Impact factor: 4.329

Review 4.  Heparinoid Complex-Based Heparin-Binding Cytokines and Cell Delivery Carriers.

Authors:  Masayuki Ishihara; Shingo Nakamura; Yoko Sato; Tomohiro Takayama; Koichi Fukuda; Masanori Fujita; Kaoru Murakami; Hidetaka Yokoe
Journal:  Molecules       Date:  2019-12-17       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.